Press releases

May 25, 2017 Invitae Broadens Management Team to Scale Expanding Business and Meet Rising Demand
- Shelly Guyer appointed chief financial officer as Lee Bendekgey takes on role of chief operating officer - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, announced that industry veteran Shelly Guyer , most recently chief financial officer at Veracyte, Inc. , a genomic diagnostics company, has been named chief financial officer, effective June 12, 2017 . Upon her appointment, Invitae's current chief financial officer, Lee Bendekgey , will fully transition to the role of chief operating officer. "I'm thrilled to be joining Invitae's team of thought leaders to help position the company as an innovator in the dynamic and ever-changing genomics market," said Shelly Guyer , future chief financial officer of Invitae . "It is an exciting time to be joining Invitae as the company continues to redefine the genetic information field and begins to evolve its business beyond the traditional scope of diagnostic testing to include industry-leading
Read more
May 12, 2017 Invitae to Present at the UBS Global Healthcare Conference
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George , chief executive officer of Invitae , will present at the UBS Global Healthcare Conference on Monday, May 22, 2017 at 11:00 a.m. Eastern / 8:00 a.m. Pacific in New York City . The live, listen-only webcast of the presentation may be accessed by visiting the Investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the company's website. About Invitae Invitae Corporation's (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae's goal is to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently
Read more
May 8, 2017 Invitae Exceeds 26,000 Samples Accessioned, Reports Revenue of $10.3 Million and Net Loss of $0.64 Per Share in First Quarter 2017
- Management expects full-year 2017 revenue between $55 million and $65 million - - Hosting conference call at 4:30 pm ET / 1:30 pm PT -   Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the quarter ended March 31, 2017 . First Quarter 2017 Financial Highlights: Generated revenue of $10.3 million in the first quarter of 2017, compared to $4.0 million in the first quarter of 2016. Accessioned more than 26,000 samples in the first quarter of 2017, representing a 166% increase over the first quarter of 2016. Reduced cost of goods sold (COGS) per sample accessioned from $612 in the first quarter of 2016 to $359 in the first quarter of 2017. Achieved positive gross profit of approximately $1.0 million in the first quarter of 2017 compared to a negative gross profit of $2.0 million in 2016. For the first quarter 2017, Invitae reported a net loss of $26.9 million, or a $0.64 loss per share,
Read more
April 28, 2017 New research suggests current genetic testing guidelines may miss breast cancer patients who could benefit from testing
- Broader use of genetic testing may better assess hereditary cancer risk in breast cancer patients and their families - New research suggests that current clinical guidelines on the use of genetic testing in breast cancer patients are too narrow and allow patients with pathogenic variants to be missed. The findings were presented at the American Society of Breast Surgeons (ASBS) Annual Meeting in Las Vegas , and come from a collaboration between TME Research , which represents more than 300 breast care practices in the United States , and Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies. Analysis of genetic test results from 249 women affected with breast cancer showed that the frequency of clinically relevant mutations was nearly the same among women who did not meet guideline criteria as among those who did meet the criteria. Among the patients who met criteria for testing, 12.7% had deleterious mutations (50% of which were BRCA1/2), while
Read more
April 27, 2017 Invitae to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George , chief executive officer, will present at the Bank of America Merrill Lynch 2017 Health Care Conference on Thursday, May 18, 2017 at 10:40 a.m. Pacific in Las Vegas . Sean George will also participate in a panel discussion titled "Genetic Testing - Pricing, Payment and Policy in a Rapidly Growing Space" on Wednesday, May 17 at 4:20 p.m. Pacific. The live webcast of the presentation may be accessed by visiting the Investors section of the company's website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the company's website. About Invitae Invitae Corporation's (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae's goal is to aggregate most of the world's genetic
Read more
April 24, 2017 Invitae to Announce First Quarter 2017 Financial Results and Host Conference Call on May 8, 2017
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its first quarter 2017 financial results on Monday, May 8, 2017 and will host a conference call that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments. The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both is 11040513. Following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations. We encourage our shareholders and those representing them to send in questions to ir@invitae.com . E-mail questions will be accepted until 4:00 p.m. Eastern / 1:00 p.m. Pacific on Monday, May 8, 2017 . The live webinar of the call may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webinar will be
Read more
April 20, 2017 Invitae announces expansion of its genetic test menu with addition of new tests and expanded panels for inherited metabolic and immune system disorders, including panels to confirm diagnoses suggested by newborn screening
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced the addition of 80 new panels alongside updates to an additional 24 panels for the diagnosis of inherited immunologic and metabolic disorders, including panels designed to confirm diagnoses suggested by newborn screening. The new and updated tests further expand the company's robust menu of high-quality, affordable diagnostic genetic tests available for use by clinicians. Many inherited metabolic disorders, such as lysosomal storage disorders, are caused by genetic changes impacting the production and regulation of enzymes that help the body function properly. Additionally, genetic changes impacting the immune system are responsible for conditions such as primary immunodeficiency (PID). Comprehensive and accurate genetic testing can help diagnose these conditions definitively and determine which gene is involved, thereby enabling patients and clinicians to make informed
Read more
April 6, 2017 Invitae expands its Genome Network with the launch of the Invitae Patient Insights Network (PIN), enabling participants to share health information and contribute to research
- A new approach to a patient registry, the Invitae PIN connects patients, clinicians, researchers, and biopharma therapeutics developers - - Permission-based, patient-centric network designed to connect patients to potential treatments and accelerate scientific discovery - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced the launch of the Invitae Patient Insights Network℠ , a permission-based, patient-centered network designed to make it easy for patients to share health experiences, contribute de-identified clinical data, and maintain their privacy while being connected to the latest research, treatment, and disease education opportunities. The Invitae Patient Insights Network (PIN) is a patient-directed approach to the traditional patient registry. The Invitae PIN enables patients with specific health conditions to share information, be connected to clinical trial and research opportunities, and contribute de-identified
Read more
April 3, 2017 Invitae announces new partnership with Alnylam Pharmaceuticals to provide TTR gene testing for patients suspected of having hereditary ATTR amyloidosis
- Offered through Invitae's Genome Network, program drives early diagnosis to help patients and their clinicians make more informed decisions about their health - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, has announced a program in partnership with Alnylam Pharmaceuticals , the leading RNAi therapeutics company, to provide genetic testing for hereditary ATTR (hATTR) amyloidosis, a rare, progressive and life-threatening disease caused by a mutation in the TTR gene which causes accumulation of misfolded proteins in nerves and cells of other organs. The Alnylam Act ™ program is aimed at encouraging early genetic testing to aid in the prompt genetic diagnosis of patients with hATTR amyloidosis. Genetic testing determines whether a patient is a carrier of a mutation in the TTR gene, thereby confirming an hATTR amyloidosis diagnosis and guiding clinical decision-making. "Genetic testing is essential for the diagnosis of hATTR to
Read more
March 30, 2017 Invitae announces introduction of exome testing
- Exome testing expands company's menu, offering an important tool for diagnosing a wide array of genetic disorders - - Test menu now includes more than 20,000 genes - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced a major expansion of its genetic testing services with the introduction of exome sequencing and interpretation services, bringing the company's available test menu to more than 20,000 genes. The Invitae Boosted Exome offers high-quality testing tailored to each patient's unique clinical situation. Exome testing can help clinicians make or confirm a diagnosis and develop an appropriate medical management plan,which is especially important in pediatric and rare disorders for which early diagnosis is essential. "Pediatric rare diseases are especially challenging to diagnose and exome testing plays a critical role," said Laurie Demmer , MD, medical geneticist at Levine Children's Specialty Center in Charlotte, NC .
Read more
March 23, 2017 Invitae Expands Test Menu for Proactive Genetic Testing in Healthy Adults
Research outlining medically actionable approach, patient experiences in pilot program presented at American College of Medical Genetics Annual Clinical Genetics Meeting Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced it has expanded the menu of tests offered as part of its ongoing proactive genetic testing pilot program. The announcement was made during the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting in Phoenix , where Invitae researchers also presented findings from the company's growing body of experience on the use of proactive testing. "Interest in using genetic information to make better health decisions is growing among patients and physicians alike. Proactive genetic testing for healthy adults can be done responsibly if it is based on proven research and focuses on actionable, useful results delivered in a clinical context, with physician guidance throughout the process," said Robert
Read more
March 22, 2017 Invitae announces expansion of its genetic testing offering to include unique test for Spinal Muscular Atrophy (SMA) during the 2017 ACMG Annual Clinical Genetics Meeting
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced the availability of a new genetic test for the diagnosis of Spinal Muscular Atrophy (SMA) , a neuromuscular disease that is one of the leading lethal genetic disorders among infants as well as a significant cause of progressive neuromuscular disease in childhood. The new test, announced during the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting , features a novel, custom methodology that offers significant improvements over current testing approaches. SMA is an autosomal recessive disorder and the second leading genetic disease in infancy behind cystic fibrosis affects. SMA affects approximately one in every 10,000 infants, while one in 50 people is a carrier for the disorder. The majority of SMA cases are caused by loss of the gene SMN1 , with variation in the number of copies of related gene, SMN2 , playing a role in mitigating the severity of the
Read more
March 14, 2017 Invitae to present seventeen posters and presentations at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced it will be presenting seventeen posters and presentations at the 2017 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting in Phoenix . "Scientific understanding of genetic medicine continues to expand rapidly, making sessions such as the ACMG meeting essential for the genetics community," said Robert Nussbaum , MD, chief medical officer of Invitae . "The research we will be presenting at ACMG this year has implications for how genetic variants are identified and classified, as well as for physicians' use of genetic information to treat patients with a wide variety of conditions. By continually advancing science, we at Invitae believe we can help more people benefit from the use of genetic information to make informed health decisions." Invitae's presence at the meeting includes two platform presentations, one on the prevalence of copy number and
Read more
February 21, 2017 Invitae to present at the Cowen and Company 37th Annual Health Care Conference
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that members of the company's management team will present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017 at approximately 4:00 p.m. Eastern / 1:00 p.m. Pacific in Boston, Massachusetts . The live, listen-only webcast of the presentation may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the company's website. About Invitae Invitae Corporation's (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae's goal is to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests
Read more
February 17, 2017 New research suggests broader genetic testing of prostate cancer patients may be warranted to identify risk of an inherited mutation that might inform treatment
- Findings presented at the 2017 Genitourinary Cancers Symposium - New research suggests that a substantial fraction of patients with prostate cancer and a positive family history are at high risk of an inherited genetic mutation that might help inform their treatment options. Among those men with prostate cancer meeting NCCN guidelines for testing, these initial data support the concept that particulars in the family history cannot be used to predict pathogenic variants. The research was presented at the 2017 Genitourinary Cancer Symposium, February 16-18 , in Orlando, Florida . Patients in the study, which was conducted by the Tulane Cancer Center in New Orleans , were tested using a commercially available panel of 25-79 cancer-related genes from Invitae (NYSE: NVTA), one of the fastest growing genetic information companies. The study, Inherited pathologic mutations and family history in patients with prostate cancer (Abstract #185), was designed to find, evaluate, and characterize
Read more
February 13, 2017 Invitae reports revenue of $9.2 million in fourth quarter 2016 and projects strong volume and revenue growth in 2017
SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the fourth quarter and full year ended December 31, 2016 and set guidance for 2017. Following are the company's financial results in 2016: Generated revenue of $9.2 million in the fourth quarter of 2016 and a total of $25.0 million for the year Reduced cost of goods sold (COGS) per sample accessioned from approximately $700 in the fourth quarter of 2015 to approximately $400 in the fourth quarter of 2016. This represents a 43% decrease in COGS per sample accessioned compared to the fourth quarter of 2015 Delivered approximately 57,000 billable reports for the full year 2016, roughly tripling the approximately 19,000 billable reports delivered in 2015. Additionally, the company reported that it accessioned approximately 59,000 samples in 2016, a nearly 200% increase compared to 2015 Delivered
Read more
January 30, 2017 Invitae to announce fourth quarter and year-end 2016 financial results and 2017 guidance and will host conference call on February 13, 2017
- Management to present at Leerink Partners 6th Annual Global Healthcare Conference on February 15, 2017 - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its fourth quarter and year-end 2016 financial results and provide 2017 guidance on Monday, February 13, 2017 , and Invitae's management team will host a conference call that day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. During the call, Invitae's management team will briefly review financial results, guidance, and recent developments and will spend the majority of the call fielding questions from analysts and investors. Management also invites investors to submit questions to ir@invitae.com at any time leading up to or during the call. The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both is 60742797. Additionally, Invitae announced that it
Read more
January 9, 2017 Invitae announces new leadership structure to drive global growth
- Sean George appointed as chief executive officer, Randy Scott to become executive chairman - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George , Ph.D., its co-founder and current president and chief operating officer, has been named chief executive officer for the company. Current chairman and chief executive officer Randy Scott will become executive chairman of the board of directors and remain full time at the company. The appointments are effective immediately. "Sean and I share a common vision for how to bring genetic testing into mainstream medical practice and a passion for transforming healthcare for people around the world. Sean has been a relentless force behind our progress toward that goal, and we're looking forward to working together in our new roles as Invitae accelerates the growth of genetic testing world-wide," said Randy Scott , executive chairman of Invitae . "Personally, I'm excited to
Read more
January 6, 2017 Invitae meets annual volume guidance, projects doubling of volume in 2017, accelerates Genome Network by acquiring scalable patient-centered data company
- Grew volume 200% by delivering approximately 57,000 billable reports for the full year 2016 and approximately 20,000 billable reports in Q4, generating positive gross margins - - Added multiple new regional payers, securing coverage for more than 175 million covered lives - - Announced new biopharma partnership and acquired patient-centered data company AltaVoice to expand the Invitae Genome Network to include both genetic information and patient-centered data - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, announced initial fourth quarter and full-year 2016 results, showing 200% year-over-year growth in billable test volume, driven by milestones including a major expansion of its test menu to more than 1,100 genes and agreements with the nation's largest payers to provide coverage for more than 175 million lives in aggregate. For the year, Invitae met its volume guidance of 50,000-70,000 billable tests, delivering approximately 57,000
Read more
January 6, 2017 Invitae acquires patient-centered data company AltaVoice, creating new offerings to advance research and access to care for patients with inherited and rare diseases
- Acquisition will enable more comprehensive understanding of inherited diseases through permission-based sharing of genetic information and patient insights - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced it has acquired AltaVoice (formerly PatientCrossroads), a privately owned, patient-centered data company with a global platform for collecting, curating, coordinating, and delivering safeguarded data from patients and clinicians. The acquisition, complemented by several other unique partnerships, expands Invitae's Genome Network, designed to connect patients, clinicians, advocacy organizations, researchers, and therapeutic developers to accelerate the understanding, diagnosis, and treatment of hereditary disease. AltaVoice amplifies the voice of patients to optimize the search for better treatments through multiple patient-centered programs, including "Patient Insights Networks℠" (PINs), which enable organizations to more
Read more

DISCLAIMER

The information in the press releases, presentations, webcasts and publications is archival and should be considered accurate only as of its date. We disclaim any obligation to supplement or update the information in these documents, presentations or webcasts.

FORWARD-LOOKING STATEMENTS

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including those risks and uncertainties detailed from time to time in Invitae Corporation’s periodic filings with the Securities and Exchange Commission. Invitae Corporation specifically disclaims any obligation to update any forward-looking statements.

Forward Looking Statements
NYSE: NVTA 8.60 +0.18 +2.14% Volume: 422,337 20 minute delay May 26, 2017

Investor Toolkit

Feature Presentation

Email Alerts

Sign up to receive Invitae financial information by email.
Email Address: *
I'D LIKE TO RECEIVE EMAILS ABOUT: *




 
Enter the code shown above.

Investor Contact

1400 16th St.
San Francisco, CA, 94103
Email: ir@invitae.com